The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in
Investor Contact:
Chief Financial Officer
investors@89bio.com
Media Contact:
773-343-3069
pduckler@w2ogroup.com
2021 GlobeNewswire, Inc., source